• 15 Apr 2021

CatSci CEO Ross Burn Included on The Medicine Maker’s 2021 Power List

We are pleased to announce that our CEO, Dr Ross Burn, has been included on the 2021 edition of The Medicine Maker’s annual Power List .
  • News

15th April 2021

We are pleased to announce that our CEO, Dr Ross Burn, has been included on the 2021 edition of The Medicine Maker’s annual Power List of inspirational professionals in the pharmaceutical industry.

Ross’ listing acknowledges his unique entrepreneurial spirit, which has been the driving force behind the exponential growth of the company. His strong vision has been critical to CatSci’s capabilities expansion from being a catalyst screening provider in 2011 to the innovation partner for medicines development that it is today.

Under Ross’ leadership, CatSci successfully secured a £3 million investment and is on track to deliver three new laboratories in Cardiff and has recently opened a second site in Dagenham ahead of schedule. This investment will allow the company to further enhance its process chemistry, material science, analytical science and pre-formulation capabilities to offer strategic value to our customers’ journey from molecule to medicine. Also, it will allow us to create over 500 high-value jobs by 2030 solidifying the UK’s position as a key player in the global pharmaceutical development industry.

Ross has been instrumental in developing the CatSci 4.0 strategy – aligning with Pharma 4.0 to become a “Digital First, Intelligent Automation Next” company. Through this digital transformation our scientists will be able to deliver innovative solutions to customers even more efficiently.

Founded in 2015, The Medicine Maker’s Power list aim to celebrate the most influential figures in small molecule, biopharmaceuticals and advanced medicine. The list includes industry professionals from Merck, Johnson & Johnson and GlaxoSmithKline.

Find out the list here.

Resources & Insights

  • 11 May 2026
CatSci Achieves ISO 27001 Certification, Demonstrating its Commitment to Client Data Security
  • News
  • 1 Apr 2026
  • Jean-Baptiste Vendeville
De-Risking Suzuki Development Through Integrated HTE and DoE
  • Analytical Chemistry
  • Chemical Development
  • Design of Experiments
  • High Throughput Experimentation
  • HTE
  • Scale-up
  • Whitepapers
2 MB
  • 23 Mar 2026
HTE-Enabled Suzuki Optimisation for Cost Reduction
  • High Throughput Experimentation
  • HTE
  • Case Studies
244 KB
  • 23 Mar 2026
  • Sam Whitmarsh
From Experiment-Centric to Data-Centric Optimisation: Introducing CHETAH – The Digital Core of Smarter, Faster High-Throughput Experimentation
  • Digital
  • High-Throughput Experimentation
  • HTE
  • Thought Leaders